Ownership Filing for Climb Bio, Inc. (CLYM)

This filing details transactions by RA Capital Management, L.P. and its affiliates concerning Climb Bio, Inc. (CLYM). RA Capital Management, L.P., acting as investment manager, and associated funds, reported the acquisition of 2,106,000 pre-funded warrants for common stock at a price of $9.4999 per share. These warrants, exercisable immediately and without expiration, are subject to a limitation where the reporting persons cannot exceed 33.0% beneficial ownership of the issuer's outstanding common stock upon exercise. Following these transactions, the post-transaction shares owned amount to 22,546,000. Notably, Dr. Andrew Levin, a Partner at the Adviser, serves on the Issuer's board of directors. The filing also clarifies beneficial ownership nuances, particularly concerning securities held by Sera Medicines, LLC.